Zacks Investment Research Upgrades Sysmex (OTCMKTS:SSMXY) to “Buy”

Zacks Investment Research upgraded shares of Sysmex (OTCMKTS:SSMXY – Get Rating) from a hold rating to a buy rating in a report issued on Thursday, Zacks.com reports. They currently have $38.00 price objective on the stock.

According to Zacks, “Sysmex Corporation is engaged in the development, manufacture, import, export and sale of clinical laboratory instruments, reagents and software used in -vitro diagnostics. It also provides clinical laboratory testing of blood, urine and other specimens. The company’s product includes instruments and reagents diagnostics for hemostasis, immunochemistry, clinical chemistry, urinalysis and point-of-care testing. Its operating segment consists of Japan, Americas, EMEA, China and Asia Pacific. Sysmex Corporation is headquartered in Kobe, Japan. “

Shares of OTCMKTS:SSMXY opened at $30.89 on Thursday. The stock has a market capitalization of $12.95 billion, a P/E ratio of 32.52 and a beta of 0.42. Sysmex has a 1-year low of $29.00 and a 1-year high of $69.41. The business has a 50-day moving average price of $34.44 and a two-hundred day moving average price of $46.91.

Sysmex Company Profile (Get Rating)

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. The company offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs.

Featured Articles